- Home
- Publications
- Publication Search
- Publication Details
Title
Diagnosis and Treatment of Chronic Lymphocytic Leukemia
Authors
Keywords
-
Journal
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 329, Issue 11, Pages 918
Publisher
American Medical Association (AMA)
Online
2023-03-21
DOI
10.1001/jama.2023.1946
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib
- (2023) Silvia Bonfiglio et al. Blood Advances
- First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial
- (2022) Carol Moreno et al. HAEMATOLOGICA
- Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
- (2022) Jeff P. Sharman et al. LEUKEMIA
- Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
- (2022) J. Joseph Melenhorst et al. NATURE
- Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors
- (2022) Eric Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
- (2022) John F. Seymour et al. BLOOD
- Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial
- (2022) Tait D. Shanafelt et al. BLOOD
- Up to 8 Years Follow-up From RESONATE-2: First-Line Ibrutinib Treatment for Patients With Chronic Lymphocytic Leukemia
- (2022) Paul M. Barr et al. Blood Advances
- Ventricular Arrhythmias and Sudden Death Events following Acalabrutinib initiation
- (2022) Seema A Bhat et al. BLOOD
- Current status of phosphoinotiside-3 kinase inhibitors in blood cancers
- (2022) Geoffrey Shouse et al. CURRENT OPINION IN ONCOLOGY
- NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
- (2022) William G. Wierda et al. Journal of the National Comprehensive Cancer Network
- Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
- (2022) Constantine S Tam et al. LANCET ONCOLOGY
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
- (2022) Rita Alaggio et al. LEUKEMIA
- Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
- (2022) Meghan C. Thompson et al. Blood Advances
- Emerging Therapies for the Management of Richter Transformation
- (2022) Elizabeth Smyth et al. JOURNAL OF CLINICAL ONCOLOGY
- Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2022) Jennifer R. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
- (2022) Mazyar Shadman et al. Lancet Haematology
- COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia
- (2022) Mazyar Shadman et al. HemaSphere
- Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
- (2021) Anthony R Mato et al. LANCET
- The CLL-international prognostic index (CLL-IPI) predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
- (2021) Sameer A Parikh et al. BLOOD
- Immune Therapy for Chronic Lymphocytic Leukemia
- (2021) Mazyar Shadman et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
- (2021) John C. Byrd et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicenter, retrospective study of accelerated venetoclax ramp‐up in patients with relapsed/refractory chronic lymphocytic leukemia
- (2021) Matthew S. Davids et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
- (2021) Tanya Siddiqi et al. BLOOD
- The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia
- (2021) Petra Langerbeins et al. BLOOD
- Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials
- (2021) John N. Allan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Breaking through BCL-2 inhibition in CLL
- (2020) Stephen J. F. Chong et al. BLOOD
- Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
- (2020) Carmen D. Herling et al. LEUKEMIA
- International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
- (2020) Adalgisa Condoluci et al. BLOOD
- Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK inhibition as an Effective Strategy
- (2020) Anthony R. Mato et al. CLINICAL CANCER RESEARCH
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2020) Paolo Ghia et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies
- (2020) Julio Delgado et al. HAEMATOLOGICA
- Treatment of Chronic Lymphocytic Leukemia
- (2020) Jan A. Burger NEW ENGLAND JOURNAL OF MEDICINE
- Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion
- (2020) Constantine S. Tam et al. HAEMATOLOGICA
- Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration
- (2020) Deborah M. Stephens et al. HAEMATOLOGICA
- Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
- (2020) Othman Al-Sawaf et al. LANCET ONCOLOGY
- Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents
- (2020) Lindsey E. Roeker et al. Blood Advances
- PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB-INTOLERANT PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
- (2019) K.A. Rogers et al. HEMATOLOGICAL ONCOLOGY
- Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
- (2019) Jeff P. Sharman et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic lymphocytic leukaemia: from genetics to treatment
- (2019) Francesc Bosch et al. Nature Reviews Clinical Oncology
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- (2019) Tait D. Shanafelt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final analysis from RESONATE: up to 6 years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
- (2019) Talha Munir et al. AMERICAN JOURNAL OF HEMATOLOGY
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
- (2018) Michael Hallek et al. BLOOD
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
- (2018) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
- (2018) Jeffrey A Jones et al. LANCET ONCOLOGY
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2018) John F. Seymour et al. NEW ENGLAND JOURNAL OF MEDICINE
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
- (2018) Ian W. Flinn et al. BLOOD
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
- (2018) Carol Moreno et al. LANCET ONCOLOGY
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
- (2017) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ONCOLOGY
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
- (2016) Barbara Eichhorst et al. LANCET ONCOLOGY
- Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL
- (2015) R. Guieze et al. BLOOD
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
- (2015) K. Fischer et al. BLOOD
- Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study
- (2015) V Goede et al. LEUKEMIA
- Management of adverse events associated with idelalisib treatment: expert panel opinion
- (2015) Steven E. Coutré et al. LEUKEMIA & LYMPHOMA
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic Lymphocytic Leukemia
- (2014) Chadi Nabhan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician
- (2014) John C. Byrd et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
- (2014) S Kamel et al. LEUKEMIA
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological aspects in chronic lymphocytic leukemia (CLL) development
- (2012) Ricardo García-Muñoz et al. ANNALS OF HEMATOLOGY
- Anti-CD20 Antibody Therapy for B-Cell Lymphomas
- (2012) David G. Maloney NEW ENGLAND JOURNAL OF MEDICINE
- General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL
- (2011) C. Fazi et al. BLOOD
- Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience
- (2009) P. Abrisqueta et al. BLOOD
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started